{"id":71431,"date":"2026-05-20T11:00:00","date_gmt":"2026-05-20T11:00:00","guid":{"rendered":"https:\/\/medsbase.com\/aicar-acadesine\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aicar-acadesine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/aicar-acadesine\/","title":{"rendered":"AICAR (Acadesine \/ AICA-Riboside)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o AICAR?<\/h3>\n<p style=\"margin: 0;\"><strong>AICAR<\/strong> (Acadesina \/ AICA-Ribos\u00eddeo \/ 5-aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, CAS 2627-69-2) \u00e9 a pequena mol\u00e9cula can\u00f3nica <strong>ativador da AMPK (prote\u00edna quinase ativada por AMP)<\/strong> used in metabolic, exercise-physiology, muscle, and cancer studies. AICAR is the cell-permeable riboside; once inside cells it is phosphorylated by adenosine kinase to the active nucleotide <strong>ZMP<\/strong> (5-aminoimidazole-4-carboxamide ribonucleotide), an AMP-mimetic that allosterically activates AMPK. Activated AMPK drives insulin-independent glucose uptake into skeletal muscle, increases fatty-acid oxidation, suppresses hepatic gluconeogenesis and de-novo lipogenesis, and inhibits mTORC1 \u2014 the canonical &#8220;exercise-in-a-pill&#8221; pharmacology. Supplied as lyophilized powder (\u226599% HPLC) for clinical studies use only. <em>N\u00e3o \u00e9 um p\u00e9ptido.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo de nucle\u00f3sido de purina de pequena mol\u00e9cula; mim\u00e9tico de AMP perme\u00e1vel \u00e0s c\u00e9lulas; ativador da AMPK; <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">5-Aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo (sin\u00f3nimos: Acadesina, AICA-Ribos\u00eddeo, NSC 105823, Z-Ribos\u00eddeo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2627-69-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">258.23 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">O ribos\u00eddeo AICA perme\u00e1vel \u00e0s c\u00e9lulas \u00e9 captado atrav\u00e9s de transportadores de adenosina e fosforilado pela adenosina quinase para formar o monofosfato intracelular ativo <strong>ZMP<\/strong> (5-aminoimidazol-4-carboxamida ribonucle\u00f3tido). O ZMP imita o AMP no dom\u00ednio Bateman da subunidade \u03b3 da AMPK, produzindo ativa\u00e7\u00e3o alost\u00e9rica da AMPK independentemente de altera\u00e7\u00f5es na rela\u00e7\u00e3o celular AMP:ATP. A AMPK ativada desencadeia ent\u00e3o o programa metab\u00f3lico de mudan\u00e7a (catabolismo \u2191, anabolismo \u2193).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (pequena mol\u00e9cula de ribonucle\u00f3sido de purina \u2014 n\u00e3o \u00e9 um p\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white crystalline powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sol\u00favel em \u00e1gua (~50 mg\/mL com aquecimento suave e agita\u00e7\u00e3o), PBS e DMSO (solu\u00e7\u00e3o estoque \u2265100 mM). As solu\u00e7\u00f5es aquosas podem necessitar de um breve aquecimento a 37 \u00b0C para dissolu\u00e7\u00e3o completa. As solu\u00e7\u00f5es de trabalho para cultura celular s\u00e3o tipicamente preparadas a 0,5\u20132 mM em meio de crescimento.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C para estoque de trabalho a curto prazo; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos (est\u00e1vel \u226536 meses a \u221220 \u00b0C). Solu\u00e7\u00f5es aquosas reconstitu\u00eddas: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Estoques em DMSO: \u221220 \u00b0C, uso ap\u00f3s descongela\u00e7\u00e3o \u00fanica. Proteger da exposi\u00e7\u00e3o prolongada \u00e0 luz. Evitar ciclos repetidos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o das solu\u00e7\u00f5es de trabalho.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 o AICAR?<\/h2>\n<p><strong>AICAR<\/strong> (5-Aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, tamb\u00e9m conhecido como Acadesina, AICA-Ribos\u00eddeo, NSC 105823 ou Z-Ribos\u00eddeo; CAS 2627-69-2) \u00e9 um an\u00e1logo de ribonucleos\u00eddeo de purina de pequena mol\u00e9cula e a ferramenta farmacol\u00f3gica mais citada para ativar <strong>prote\u00edna quinase ativada por AMP (AMPK)<\/strong> in cell-culture, primary-cell, and rodent in-vivo studies. It is <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em> \u2014 \u00e9 um ribonucleos\u00eddeo sint\u00e9tico com a f\u00f3rmula molecular C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub> and a molecular weight of 258.23 g\/mol. MedsBase stocks it in the same lyophilized-vial format as our peptide catalogue for convenience of reconstitution and dosing in mixed-protocol AMPK \/ metabolic \/ mitochondrial studies. AICAR was originally developed in the 1990s by Acadesine Inc. (later Schering-Plough) as a candidate cardioprotective agent for coronary artery bypass surgery \u2014 the compound completed Phase III trials but did not gain regulatory approval. Its pharmacological utility, however, has only expanded since: AICAR is now the standard reference compound for AMPK activation in published studies, and the AMPK pathway it engages has been implicated in nearly every major area of metabolic biology \u2014 insulin sensitivity, type-2 diabetes, fatty-acid oxidation, exercise physiology, muscle hypertrophy \/ atrophy, mitochondrial biogenesis, cancer metabolism, autophagy, and ageing. In published studies AICAR is described as an &#8220;exercise mimetic&#8221; because chronic administration in sedentary mice has been reported to drive a skeletal-muscle gene-expression signature, mitochondrial-biogenesis programme, and endurance-performance phenotype that broadly mimics the effects of voluntary wheel running \u2014 the original 2008 Narkar et\u00a0al. publication in <em>Cell<\/em> (\u201cAMPK e PPAR\u03b4 Agonistas S\u00e3o Mim\u00e9ticos do Exerc\u00edcio\u201d) \u00e9 o artigo mais citado nesta \u00e1rea. O AICAR tamb\u00e9m est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA (classe S4.5, Moduladores Metab\u00f3licos) e \u00e9 proibido no desporto em qualquer momento devido a este potencial de melhoria de desempenho. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Ativa\u00e7\u00e3o Celular da AMPK via ZMP<\/h2>\n<p>O mecanismo do AICAR \u00e9 o mais caracterizado de qualquer ativador farmacol\u00f3gico da AMPK:<\/p>\n<ul>\n<li><strong>Entrada na c\u00e9lula via transportadores de adenosina<\/strong> \u2014 O AICAR (o ribos\u00eddeo) \u00e9 em si biologicamente inerte. \u00c9 absorvido pelas c\u00e9lulas atrav\u00e9s dos mesmos transportadores de adenosina equilibradores e concentradores (ENT1, ENT2, CNT2, CNT3) que movem a adenosina end\u00f3gena e outros nucleos\u00eddeos de purina atrav\u00e9s da membrana plasm\u00e1tica. A distribui\u00e7\u00e3o tecidual e a cin\u00e9tica de concentra\u00e7\u00e3o in vivo s\u00e3o governadas por estes transportadores.<\/li>\n<li><strong>Fosforila\u00e7\u00e3o intracelular a ZMP por adenosina quinase<\/strong> \u2014 Uma vez intracelular, o AICAR \u00e9 fosforilado pela <strong>adenosina quinase (AK)<\/strong> on its 5\u2032-hydroxyl, generating the active metabolite ZMP (5-aminoimidazole-4-carboxamide ribonucleotide). ZMP is the immediate AMP analogue and is the species that actually engages AMPK. Adenosine kinase activity is therefore the rate-limiting step for AICAR pharmacology in any given tissue \u2014 protocols that use AK-deficient cells or AK inhibitors confirm that ZMP, not AICAR itself, is the active species.<\/li>\n<li><strong>Ativa\u00e7\u00e3o alost\u00e9rica da AMPK na subunidade \u03b3<\/strong> \u2014 O ZMP liga-se aos mesmos s\u00edtios CBS do dom\u00ednio Bateman na subunidade \u03b3 da AMPK que o AMP end\u00f3geno ocupa em condi\u00e7\u00f5es de baixa energia. A liga\u00e7\u00e3o do ZMP produz tr\u00eas efeitos alost\u00e9ricos convergentes na AMPK: (1) estimula\u00e7\u00e3o alost\u00e9rica da atividade catal\u00edtica, (2) prote\u00e7\u00e3o da fosforila\u00e7\u00e3o da Thr172 na subunidade \u03b1 da AMPK contra a desfosforila\u00e7\u00e3o pela PP2C, e (3) aumento da fosforila\u00e7\u00e3o da Thr172 pelas quinases upstream LKB1 e CaMKK2. O resultado l\u00edquido \u00e9 uma ativa\u00e7\u00e3o sustentada e de alto n\u00edvel da AMPK que \u00e9 independente de altera\u00e7\u00f5es na rela\u00e7\u00e3o real AMP:ATP celular.<\/li>\n<li><strong>Mudan\u00e7a metab\u00f3lica downstream \u2014 upregula\u00e7\u00e3o catab\u00f3lica<\/strong> \u2014 Activated AMPK phosphorylates a large set of metabolic effectors that drive the catabolic \/ energy-generating programme: ACC (acetyl-CoA carboxylase, on Ser79 and Ser212) \u2014 relieving malonyl-CoA inhibition of CPT-I and allowing long-chain fatty acids into the mitochondria for \u03b2-oxidation; HSL (hormone-sensitive lipase) \u2014 increasing adipocyte lipolysis; TBC1D1 \u2014 driving insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle; PGC-1\u03b1 \u2014 driving mitochondrial biogenesis. The skeletal-muscle glucose-uptake effect is the most-cited functional readout in AMPK studies.<\/li>\n<li><strong>Mudan\u00e7a metab\u00f3lica downstream \u2014 supress\u00e3o anab\u00f3lica<\/strong> \u2014 A AMPK ativada suprime simultaneamente vias anab\u00f3licas \/ consumidoras de energia: a fosforila\u00e7\u00e3o da TSC2 e da Raptor inibe a mTORC1, suprimindo a s\u00edntese proteica e desencadeando a autofagia; a fosforila\u00e7\u00e3o da HMG-CoA redutase suprime a s\u00edntese de colesterol; a fosforila\u00e7\u00e3o da SREBP1c suprime a lipog\u00e9nese hep\u00e1tica de novo; a fosforila\u00e7\u00e3o da PFKFB3 e da ACC suprime a s\u00edntese de glicog\u00e9nio e de \u00e1cidos gordos. A combina\u00e7\u00e3o da upregula\u00e7\u00e3o catab\u00f3lica \/ downregula\u00e7\u00e3o anab\u00f3lica \u00e9 a farmacologia can\u00f3nica da AMPK.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of AICAR is broadly favourable for use \u2014 oral bioavailability is modest but workable, intraperitoneal administration in rodents produces reliable systemic exposure within 30 minutes, and the plasma half-life of the parent riboside is on the order of 90 minutes (the half-life of the intracellular ZMP metabolite is longer, sustaining AMPK activation for several hours after a single bolus dose). Typical in-vivo rodent protocols use 250\u2013500\u00a0mg\/kg administered IP daily; high doses (1\u00a0g\/kg) have been used in some published muscle-physiology studies. In-vitro cell culture work typically uses 0.5\u20132\u00a0mM in growth medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AICAR is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia da AMPK \u2014 o ativador de refer\u00eancia can\u00f3nico<\/strong> \u2014 by far the most-cited small-molecule AMPK activator in the published literature; standard tool compound for any new AMPK-pathway studies; reference compound against which all newer direct AMPK activators (A769662, MK-8722, PF-739, O304, the metformin class) are benchmarked<\/li>\n<li><strong>Sensibilidade \u00e0 insulina e capta\u00e7\u00e3o de glucose no m\u00fasculo esquel\u00e9tico<\/strong> \u2014 AICAR drives insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle via the AMPK-TBC1D1 axis; widely used in studies on type-2 diabetes, insulin-resistance reversal, and skeletal-muscle metabolic flexibility<\/li>\n<li><strong>Exercise mimetic and endurance studies<\/strong> \u2014 o quadro \u201cAMPK e Agonistas PPAR\u03b4 S\u00e3o Mimetizadores do Exerc\u00edcio\u201d de Narkar et al. (2008,) continua a ser o artigo mais citado sobre o AICAR; protocolos publicados em roedores documentam aumento da resist\u00eancia, convers\u00e3o de fibras de contra\u00e7\u00e3o lenta (Tipo I) e melhoria da capacidade oxidativa ap\u00f3s 4 semanas de administra\u00e7\u00e3o de AICAR em ratos sedent\u00e1rios, <em>Cell<\/em>) O quadro \u201cAMPK e PPAR\u03b4 Agonistas s\u00e3o Mim\u00e9ticos de Exerc\u00edcio\u201d continua a ser o artigo mais citado sobre o AICAR; protocolos publicados em roedores documentam o aumento da resist\u00eancia, a convers\u00e3o de fibras de contra\u00e7\u00e3o lenta (Tipo I) e a melhoria da capacidade oxidativa ap\u00f3s 4 semanas de administra\u00e7\u00e3o de AICAR em ratos sedent\u00e1rios<\/li>\n<li><strong>Supress\u00e3o da gliconeog\u00e9nese e lipog\u00e9nese hep\u00e1ticas<\/strong> \u2014 AICAR suppresses hepatic glucose output via AMPK-mediated phosphorylation of transcriptional co-activators (CRTC2, HNF4\u03b1); also suppresses hepatic de-novo lipogenesis via SREBP1c phosphorylation; used in non-alcoholic fatty liver disease (NAFLD) and metabolic-dysfunction-associated steatohepatitis (MASH) preclinical studies<\/li>\n<li><strong>Fatty-acid oxidation studies<\/strong> \u2014 O AICAR fosforila a ACC, alivia a inibi\u00e7\u00e3o da CPT-I pelo malonil-CoA e direciona os \u00e1cidos gordos de cadeia longa para as mitoc\u00f4ndrias para \u03b2-oxida\u00e7\u00e3o; a interven\u00e7\u00e3o farmacol\u00f3gica can\u00f3nica para aumentar a oxida\u00e7\u00e3o de \u00e1cidos gordos em hepat\u00f3citos prim\u00e1rios, cardiomi\u00f3citos e miotubos de m\u00fasculo esquel\u00e9tico<\/li>\n<li><strong>Cancer metabolism studies<\/strong> \u2014 many cancer cells display elevated lipogenesis (via SREBP1c) and elevated mTORC1 signalling; AICAR suppresses both via AMPK activation and has been investigated in published studies on acute lymphoblastic leukaemia (the historical original indication for Acadesine), prostate cancer, breast cancer, and other tumour models<\/li>\n<li><strong>Autophagy and mTORC1-inhibition studies<\/strong> \u2014 AICAR triggers autophagy via dual phosphorylation of TSC2 (Ser1387) and Raptor (Ser792), both of which inhibit mTORC1; used as a pharmacological intervention in autophagy-induction studies alongside rapamycin and starvation models<\/li>\n<li><strong>Mitochondrial biogenesis studies<\/strong> \u2014 O AICAR estimula a express\u00e3o e atividade da PGC-1\u03b1, aumentando a biog\u00e9nese mitocondrial no m\u00fasculo esquel\u00e9tico e no tecido adiposo castanho; complementar a <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo derivado mitocondrial ativador da AMPK) em protocolos que exploram a redund\u00e2ncia da via da AMPK<\/li>\n<li><strong>Cardioprotection studies<\/strong> \u2014 the original clinical indication; AICAR has been used in ischaemia-reperfusion injury models and the cardiac-surgery cardioprotection paradigm; preclinical studies continues despite Phase III not gaining approval<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre AMPK \/ NAD<sup>+<\/sup> \/ metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo derivado mitocondrial ativador da AMPK \u2014 o an\u00e1logo pept\u00eddico mais pr\u00f3ximo), <a href=\"https:\/\/medsbase.com\/pt-pt\/5-amino-1mq\/\">5-Amino-1MQ<\/a> (inibidor de NNMT; complementar NAD<sup>+<\/sup>(coenzima dinucle\u00f3tido oxidada, substrato central do transporte de eletr\u00f5es), e, <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> (transporte mitocondrial de \u00e1cidos gordos de cadeia longa). Explore a lista completa <a href=\"https:\/\/medsbase.com\/pt-pt\/l-carnitine\/\">L-Carnitina<\/a> (transporte mitocondrial de \u00e1cidos gordos de cadeia longa). Navegue na lista completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">peptides &amp; compounds catalog<\/a> para compostos relacionados, ou consulte os <a href=\"https:\/\/medsbase.com\/pt-pt\/best-longevity-peptides\/\">longevity compounds<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> centrais. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks AICAR in a single lyophilized vial size calibrated to typical in-vivo and high-throughput in-vitro protocols. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 single-cohort in-vivo rodent dosing (250\u2013500\u00a0mg\/kg IP daily for 2\u20134 weeks covers a 30-g mouse cohort with one 50\u00a0mg vial per ~2\u20133 doses), high-throughput in-vitro AMPK-activation panels (0.5\u20132\u00a0mM working concentrations), reconstitution-and-dose-titration work, primary-hepatocyte \/ myotube fatty-acid-oxidation panels<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 50\u00a0mg vial format provides a convenient dosing unit for most published in-vivo rodent protocols and supports the 0.5\u20132\u00a0mM working concentrations used in cell-culture AMPK-activation studies. The 30-vial pack is the more economical purchase per-mg for extended-cycle or large-cohort protocols (4\u20138 week chronic dosing, multi-cohort exercise-mimetic studies). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Comparar \u2014 AICAR vs MOTS-c<\/h2>\n<p>AICAR e <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> are the two most-studied AMPK-activating compounds in this catalogue, and they target the AMPK pathway via mechanistically distinct routes. AICAR is a small-molecule cell-permeable AMP-mimetic that drives AMPK activation directly at the \u03b3-subunit. MOTS-c is a mitochondrial-derived 16-amino-acid peptide that translocates to the nucleus under metabolic stress and activates AMPK indirectly through a folate-pathway \/ methionine-cycle intermediate (AICAR-like increase in cellular AICAR \/ ZMP levels). The two compounds are mechanistically complementary in published combination studies, and the comparison illustrates one of the most-studied &#8220;small-molecule vs peptide&#8221; dyads in AMPK biology. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AICAR<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pequena mol\u00e9cula de ribonucleos\u00eddeo de purina (mimetizador de AMP perme\u00e1vel \u00e0s c\u00e9lulas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido derivado mitocondrial de 16 res\u00edduos (via MTHFD2L \/ mecanismo de acumula\u00e7\u00e3o semelhante ao AICAR)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">258.23 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2,174 g\/mol (p\u00e9ptido de 16 res\u00edduos)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Via para a AMPK<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Direta \u2014 fosforilada para ZMP intracelularmente, liga-se ao dom\u00ednio Bateman da subunidade \u03b3 da AMPK (mimetizador de AMP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indireta \u2014 perturba o ciclo do folato\/metionina, aumenta o AICAR\/ZMP celular, ativa a AMPK atrav\u00e9s do mesmo s\u00edtio alost\u00e9rico da subunidade \u03b3<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mimetizador de exerc\u00edcio, sensibilidade \u00e0 insulina, gluconeog\u00e9nese hep\u00e1tica, metabolismo do cancro, autofagia, biog\u00e9nese mitocondrial<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sensibilidade \u00e0 insulina, biologia mitocondrial, decl\u00ednio metab\u00f3lico relacionado com a idade, longevidade, farmacologia do eixo pept\u00eddico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estabilidade no plasma<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~90 min de meia-vida plasm\u00e1tica (ribos\u00eddeo parental); o ZMP intracelular mant\u00e9m o efeito durante v\u00e1rias horas por dose bolus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short \u2014 minutes of plasma half-life unprotected; supports IP \/ SC dosing in studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mg\/kg IP diariamente em roedores (ocasionalmente 1 g\/kg em protocolos de fisiologia muscular); 0,5\u20132 mM em cultura celular<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,5\u20135 mg\/kg IP\/SC em roedores<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de seletividade\/efeitos fora do alvo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00e3o \u00e9 puramente seletivo \u2014 o ZMP tamb\u00e9m afeta a sinaliza\u00e7\u00e3o da adenosina, a frutose-1,6-bisfosfatase e a AMP-desaminase em doses elevadas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Seletividade da classe pept\u00eddica \u2014 menos efeitos documentados em recetores de pequenas mol\u00e9culas fora do alvo, mas a identidade do recetor permanece sob investiga\u00e7\u00e3o<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado regulamentar<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sem aprova\u00e7\u00e3o cl\u00ednica (Acadesina Fase III para CABG n\u00e3o obteve aprova\u00e7\u00e3o); Lista de Proibidos da WADA S4.5 (proibido no desporto em qualquer momento)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No clinical approval; studies-only peptide<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on direct, high-magnitude AMPK activation with the canonical small-molecule reference tool, AICAR is the standard compound. For studies focused on peptide-class AMPK activation, mitochondrial-derived signalling, or longevity-axis peptide pharmacology, <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> \u00e9 a ferramenta mais direcionada. Consulte tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-pt\/5-amino-1mq\/\">5-Amino-1MQ<\/a> for NAD-axis precursor-sparing studies, <a href=\"https:\/\/medsbase.com\/pt-pt\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-binding mitochondrial-targeted studies, and <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> para suplementa\u00e7\u00e3o direta do pool de NAD. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo, congele os frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226512 meses a 2\u20138 \u00b0C). O AICAR liofilizado \u00e9 substancialmente mais est\u00e1vel do que a maioria dos pept\u00eddeos liofilizados porque o ribonucleos\u00eddeo de pequena mol\u00e9cula n\u00e3o tem liga\u00e7\u00f5es amida ou pontes dissulfeto para hidrolisar. Proteja da exposi\u00e7\u00e3o prolongada \u00e0 luz direta. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> para o frasco de 50 mg, injete 1,0 mL de \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou PBS est\u00e9ril pela parede lateral do frasco \u2014 isto produz um stock de trabalho de 50 mg\/mL (~193 mM). Para stocks de trabalho mais dilu\u00eddos, 2,5 mL produzem 20 mg\/mL (~77 mM), e 5,0 mL produzem um stock de trabalho de 10 mg\/mL (~39 mM). O AICAR dissolve-se rapidamente com agita\u00e7\u00e3o suave \u00e0 temperatura ambiente; um breve aquecimento a 37 \u00b0C acelera a dissolu\u00e7\u00e3o se estiverem presentes cristais residuais de armazenamento a frio. Para trabalho in vitro com culturas celulares, o DMSO tamb\u00e9m \u00e9 um solvente de reconstitui\u00e7\u00e3o adequado (stock at\u00e9 200 mM); dilua as solu\u00e7\u00f5es de trabalho em meio aquoso imediatamente antes do uso, visando uma concentra\u00e7\u00e3o final de 0,5\u20132 mM no meio de crescimento. Uma vez reconstitu\u00eddo em tamp\u00e3o aquoso, armazene o frasco a 2\u20138 \u00b0C e use-o dentro de 30 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a de cor acentuada. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O AICAR \u00e9 um pept\u00eddeo?<\/h3>\n<p>N\u00e3o. O AICAR \u00e9 um an\u00e1logo de ribonucleos\u00eddeo de purina de pequena mol\u00e9cula (MW 258,23 g\/mol), <em>n\u00e3o<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/pt-pt\/5-amino-1mq\/\">5-Amino-1MQ<\/a>, <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/l-carnitine\/\">L-Carnitina<\/a> because it serves a complementary role in mitochondrial \/ metabolic \/ AMPK-axis studies and is supplied in the same lyophilized vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre AICAR, Acadesina, AICA-Ribos\u00eddeo e ZMP?<\/h3>\n<p>AICAR, Acadesina, AICA-Ribos\u00eddeo, NSC 105823 e Z-Ribos\u00eddeo s\u00e3o <em>todos o mesmo composto<\/em> \u2014 cinco nomes diferentes para 5-aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, o ribos\u00eddeo perme\u00e1vel \u00e0 c\u00e9lula (CAS 2627-69-2). <strong>ZMP<\/strong> is a different compound \u2014 the intracellular monophosphate (5-aminoimidazole-4-carboxamide ribonucleotide), generated by adenosine kinase from the riboside once it has entered the cell. ZMP is the actual AMP-mimetic that engages AMPK; the riboside itself (AICAR) is the cell-permeable pro-drug. Studies suppliers sell the riboside because it is cell-permeable; the monophosphate (ZMP) does not cross the plasma membrane. <\/p>\n<h3>Por que \u00e9 que o AICAR \u00e9 chamado de \u201cmim\u00e9tico do exerc\u00edcio\u201d?<\/h3>\n<p>O artigo de Narkar et\u00a0al. (2008) intitulado \u201cAMPK e PPAR\u03b4 Agonistas S\u00e3o Mimetizadores de Exerc\u00edcio\u201d relatou que 4 semanas de administra\u00e7\u00e3o de AICAR a ratos sedent\u00e1rios (500\u00a0mg\/kg\/d IP) produziram uma assinatura de express\u00e3o gen\u00e9tica no m\u00fasculo esquel\u00e9tico, um perfil de biog\u00e9nese mitocondrial, uma mudan\u00e7a no tipo de fibra para fibras oxidativas de contra\u00e7\u00e3o lenta (Tipo I) e um fen\u00f3tipo de desempenho de resist\u00eancia que imitou amplamente os efeitos da corrida volunt\u00e1ria em roda em ratos n\u00e3o tratados. A express\u00e3o \u201cexerc\u00edcio num comprimido\u201d tem origem neste artigo. O AICAR est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA em parte devido a estes resultados de melhoria de desempenho. <em>Cell<\/em> O artigo \u201cAMPK e PPAR\u03b4 Agonists Are Exercise Mimetics\u201d relatou que 4 semanas de administra\u00e7\u00e3o de AICAR a ratos sedent\u00e1rios (500 mg\/kg\/dia IP) produziram uma assinatura de express\u00e3o gen\u00e9tica no m\u00fasculo esquel\u00e9tico, um perfil de biog\u00e9nese mitocondrial, uma mudan\u00e7a no tipo de fibra para fibras oxidativas de contra\u00e7\u00e3o lenta (Tipo I) e um fen\u00f3tipo de desempenho de resist\u00eancia que imitou amplamente os efeitos da corrida volunt\u00e1ria em roda em ratos n\u00e3o tratados. A express\u00e3o \u201cexerc\u00edcio num comprimido\u201d deriva deste artigo. O AICAR est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA em parte devido a estes resultados de melhoria de desempenho. <\/p>\n<h3>What published dose ranges have been used in mouse and rat studies?<\/h3>\n<p>The most-cited mouse-protocol dose is 250\u2013500\u00a0mg\/kg IP daily, administered for 2\u20134 weeks. The endurance-phenotype Narkar et\u00a0al. protocol used 500\u00a0mg\/kg\/d IP for 4 weeks. Higher doses (up to 1\u00a0g\/kg) have been used in some muscle-physiology studies. Rat protocols are similar (250\u2013500\u00a0mg\/kg IP). In-vitro cell-culture work typically uses 0.5\u20132\u00a0mM AICAR in growth medium. Users should consult primary literature (Narkar et\u00a0al. 2008; Corton et\u00a0al. 1995 original AMPK-activation paper; Merrill et\u00a0al. 1997 skeletal-muscle glucose-uptake paper) for species-, model-, and endpoint-specific dosing guidance. <\/p>\n<h3>Qual \u00e9 o estatuto regulamentar da AICAR segundo a WADA?<\/h3>\n<p>AICAR \/ Acadesine is listed on the World Anti-Doping Agency (WADA) Prohibited List under class S4.5 (Hormone and Metabolic Modulators) and is prohibited in sport at all times \u2014 both in-competition and out-of-competition. The basis is the exercise-mimetic endurance-phenotype finding. Users conducting human-subject studies with AICAR need to be aware of this status (in addition to regulatory requirements for any unapproved drug). For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>Como \u00e9 que o AICAR se compara \u00e0 metformina enquanto ativador da AMPK?<\/h3>\n<p>Tanto o AICAR como a metformina ativam a AMPK, mas atrav\u00e9s de vias ascendentes completamente diferentes. O AICAR (ap\u00f3s convers\u00e3o intracelular em ZMP) \u00e9 um <em>mimetizador de AMP que se liga ao dom\u00ednio Bateman da subunidade \u03b3 da AMPK. A metformina \u00e9 um<\/em> Mim\u00e9tico de AMP que se liga ao dom\u00ednio Bateman da subunidade \u03b3 da AMPK. A Metformina \u00e9 um <em>indirect<\/em> Ativador de AMPK \u2014 inibe o complexo I mitocondrial, o que reduz o ATP e aumenta a raz\u00e3o AMP:ATP, ativando secundariamente a AMPK atrav\u00e9s do mecanismo natural de liga\u00e7\u00e3o ao AMP. Os dois compostos, portanto, exploram diferentes camadas da via da AMPK: o AICAR\/ZMP contorna a necessidade de stress energ\u00e9tico real, enquanto a metformina envolve o ramo natural de dete\u00e7\u00e3o de energia. Os novos ativadores diretos da AMPK (A769662, MK-8722, PF-739, O304) ligam-se a um terceiro local (a bolsa alost\u00e9rica da subunidade \u03b2\/ADaM) e oferecem melhor seletividade de isoforma do que o AICAR ou a metformina. <\/p>\n<h3>O AICAR pode ser combinado com MOTS-c, NAD<sup>+<\/sup>, or 5-Amino-1MQ in protocols?<\/h3>\n<p>Yes \u2014 the four compounds target overlapping but mechanistically distinct nodes of mitochondrial \/ AMPK \/ NAD-axis biology and are commonly combined in studies that aims to dissect direct AMPK activation (AICAR) from peptide-class AMPK activation (<a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a>), da poupan\u00e7a de precursores de NAD (<a href=\"https:\/\/medsbase.com\/pt-pt\/5-amino-1mq\/\">5-Amino-1MQ<\/a>), da suplementa\u00e7\u00e3o direta do pool de NAD (<a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a>). Reconstitua cada um separadamente primeiro para estabelecer estabilidade e precis\u00e3o de concentra\u00e7\u00e3o, e combine imediatamente antes de usar em vez de armazenar conjuntamente os frascos reconstitu\u00eddos. As combina\u00e7\u00f5es mais publicadas s\u00e3o AICAR + metformina (ativa\u00e7\u00e3o dupla da AMPK, ramos ascendentes diferentes) e AICAR + rapamicina (inibi\u00e7\u00e3o dupla da mTORC1, mecanismos diferentes). <\/p>\n<h3>Por que a Acadesina n\u00e3o obteve aprova\u00e7\u00e3o cl\u00ednica?<\/h3>\n<p>Acadesine (the clinical-trial name for AICAR) completed two large Phase III trials for cardioprotection in coronary artery bypass surgery (CABG) in the 1990s. The trials did not demonstrate statistically significant reductions in the primary composite endpoint (myocardial infarction, stroke, cardiovascular death), and the development programme was discontinued. AICAR remains a tool compound rather than an approved drug, although a number of academic groups have continued to investigate the cardioprotection paradigm and the broader AMPK-pathway pharmacology. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Compounds for AMPK and Metabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Pept\u00eddeo derivado mitocondrial ativador de AMPK \u2014 an\u00e1logo pept\u00eddico mecanicamente mais pr\u00f3ximo<\/li>\n<li><a href=\"\/pt-pt\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 Inibidor seletivo de NNMT \u2014 abordagem complementar de poupan\u00e7a de precursores de NAD<\/li>\n<li><a href=\"\/pt-pt\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 Oxidised dinucleotide coenzyme \u2014 direct NAD-pool supplementation studies<\/li>\n<li><a href=\"\/pt-pt\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Pept\u00eddeo mitocondrial direcionado \u00e0 cardiolipina<\/li>\n<li><a href=\"\/pt-pt\/l-carnitine\/\"><strong>L-Carnitina<\/strong><\/a> \u2014 Transportador mitocondrial de \u00e1cidos gordos de cadeia longa \u2014 mol\u00e9cula pequena companheira<\/li>\n<li><a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, conservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Ativador can\u00f3nico de AMPK de mol\u00e9cula pequena (mimetizador de AMP perme\u00e1vel \u00e0 c\u00e9lula via ZMP)<br \/>\n\u2705 Promove a capta\u00e7\u00e3o de glucose independente da insulina no m\u00fasculo esquel\u00e9tico<br \/>\n\u2705 Suprime a gliconeog\u00e9nese hep\u00e1tica, a lipog\u00e9nese de novo e a s\u00edntese de colesterol<br \/>\n\u2705 Fen\u00f3tipo de \u2018mimetizador de exerc\u00edcio\u2019 publicado (Narkar et al. 2008, Cell)<br \/>\n\u2705 Composto de refer\u00eancia para farmacologia da AMPK \u2014 PM 258.23, CAS 2627-69-2<\/p>\n<p><strong>AICAR<\/strong> contains 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside compound.<\/p>","protected":false},"featured_media":71435,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6486,6487,6485,6488,6489,6484,6482],"class_list":["post-71431","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-acadesine","product_tag-aica-riboside","product_tag-aicar","product_tag-ampk-activator","product_tag-exercise-mimetic","product_tag-metabolic-research","product_tag-research-compound","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71435"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71431"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71431"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71431"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}